With the proliferation of metabolic-related diseases such as diabetes, biopharmaceutical companies are working to develop new therapies that address these conditions. Companies large and small are expending precious resources to find treatments for people who have developed diabetes to lessen the likelihood of serious complications such as diabetic retinopathy, coronary artery disease and stroke.